278 related articles for article (PubMed ID: 28403051)
1. Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy.
Majekodunmi AO; Thorne C; Malyuta R; Volokha A; Callard RE; Klein NJ; Lewis J;
Pediatr Infect Dis J; 2017 May; 36(5):e123-e129. PubMed ID: 28403051
[TBL] [Abstract][Full Text] [Related]
2. Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.
BenMarzouk-Hidalgo OJ; Torres-Cornejo A; Gutierrez-Valencia A; Ruiz-Valderas R; Viciana P; López-Cortés LF
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):6-11. PubMed ID: 26414169
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.
Avidan NU; Goldstein D; Rozenberg L; McLaughlin M; Ferenci P; Masur H; Buti M; Fauci AS; Polis MA; Kottilil S
J Acquir Immune Defic Syndr; 2009 Dec; 52(4):452-8. PubMed ID: 19797971
[TBL] [Abstract][Full Text] [Related]
4. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
[TBL] [Abstract][Full Text] [Related]
5. Quantification of hepatic FOXP3+ T-lymphocytes in HIV/hepatitis C coinfection.
Williams SK; Donaldson E; Van der Kleij T; Dixon L; Fisher M; Tibble J; Gilleece Y; Klenerman P; Banham AH; Howard M; Webster DP
J Viral Hepat; 2014 Apr; 21(4):251-9. PubMed ID: 24597693
[TBL] [Abstract][Full Text] [Related]
6. Transient liver injury associated with the early recovery of HCV-specific T-cell responses and HCV rebound in HIV-1/HCV coinfected patients undergoing highly active antiretroviral therapy.
Kang F; Chen W; Zhang X; Nie W; Fu J; Xu X; Zhao P; Zhang X; Li W; Wang FS; Zhang Z; Zhao M
J Acquir Immune Defic Syndr; 2013 Feb; 62(2):135-42. PubMed ID: 23075912
[TBL] [Abstract][Full Text] [Related]
7. Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients.
Grubczak K; Grzeszczuk A; Groth M; Hryniewicz A; Kretowska-Grunwald A; Flisiak R; Moniuszko M
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452314
[TBL] [Abstract][Full Text] [Related]
8. Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.
Capa L; Soriano V; García-Samaniego J; Nuñez M; Romero M; de Mendoza C; Cascajero A; Muñoz F; González-Lahoz J; Benito JM
Antivir Ther; 2007; 12(4):459-68. PubMed ID: 17668554
[TBL] [Abstract][Full Text] [Related]
9. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy.
Potter M; Odueyungbo A; Yang H; Saeed S; Klein MB;
AIDS; 2010 Jul; 24(12):1857-65. PubMed ID: 20479633
[TBL] [Abstract][Full Text] [Related]
10. Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia.
Taye S; Lakew M
BMC Immunol; 2013 May; 14():23. PubMed ID: 23679118
[TBL] [Abstract][Full Text] [Related]
11. Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Milazzo L; Foschi A; Mazzali C; Viola A; Ridolfo A; Galli M; Antinori S
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):989-93. PubMed ID: 22220723
[TBL] [Abstract][Full Text] [Related]
12. Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfected patients.
Reiberger T; Payer BA; Kosi L; Heil PM; Rieger A; Peck-Radosavljevic M;
J Infect Dis; 2011 Jun; 203(12):1802-6. PubMed ID: 21606538
[TBL] [Abstract][Full Text] [Related]
13. Impact of Hepatitis C Virus on the Circulating Levels of IL-7 in HIV-1 Coinfected Women.
Kerzerho J; McIlvaine EJ; Anthony P; Mack WJ; Wang CH; Frederick T; Operskalski E; Chen Z; Al-Harthi L; Landay A; Young MA; Tien PC; Augenbraun M; Strickler HD; Akbari O; Golub ET; Sharp GB; Kovacs A
J Acquir Immune Defic Syndr; 2016 Feb; 71(2):172-80. PubMed ID: 26761519
[TBL] [Abstract][Full Text] [Related]
14. Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.
Mandorfer M; Neukam K; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Ernst D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M; Reiberger T
Antivir Ther; 2014; 19(4):407-14. PubMed ID: 24342953
[TBL] [Abstract][Full Text] [Related]
15. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
16. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
[TBL] [Abstract][Full Text] [Related]
17. HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals.
Rallón NI; Soriano V; Restrepo C; García-Samaniego J; Labarga P; López M; Peris A; González-Lahoz J; Benito JM
J Acquir Immune Defic Syndr; 2011 May; 57(1):1-8. PubMed ID: 21786458
[TBL] [Abstract][Full Text] [Related]
18. Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy.
Gutiérrez-Saborido D; Gutiérrez-Valencia A; González Domenech CM; López Ruz MÁ; Raffo Márquez M; Omar M; Girón-González JA;
Ann Hematol; 2019 Aug; 98(8):1953-1959. PubMed ID: 31025161
[TBL] [Abstract][Full Text] [Related]
19. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
[TBL] [Abstract][Full Text] [Related]
20. Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.
Hua S; Vigano S; Tse S; Zhengyu O; Harrington S; Negron J; Garcia-Broncano P; Marchetti G; Genebat M; Leal M; Resino S; Ruiz-Mateos E; Lichterfeld M; Yu XG
Clin Infect Dis; 2018 Jun; 66(12):1910-1917. PubMed ID: 29272392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]